Related Experiment Video

Updated: Dec 21, 2025

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.3K

Small airways in children with allergic rhinoconjunctivitis: the potential role of a multicomponent nutraceutical

Salvatore Leonardi1, Giuseppe Parisi2, Maria Papale2

  • 1Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy University . gio.cip@libero.it.

Acta Bio-Medica : Atenei Parmensis
|May 19, 2020
PubMed

Insights

A multicomponent nutraceutical may prevent the decline in MEF50 (maximal expiratory flow at 50% of forced vital capacity) in children with allergic rhinoconjunctivitis, suggesting a way to manage early bronchial involvement.

Area of Science:

  • Pediatrics
  • Allergology
  • Pulmonology

Background:

  • Allergic rhinitis (AR) and asthma are closely linked, with rhinitis often preceding asthma development.
  • Spirometry parameters like FEF25-75 and MEF50 can indicate small airway patency and predict early bronchial issues in AR patients.

Purpose of the Study:

  • To evaluate spirometry changes over time in children with AR.
  • To assess the effect of a multicomponent nutraceutical on spirometry parameters in children with AR.

Main Methods:

  • Two groups of children with AR were studied: an active group (AG) receiving a nutraceutical and a control group (CG).
  • Spirometry (FEV1, FVC, MEF50) was measured at baseline, after the nutraceutical course, and after 1 year.

Main Results:

  • After one year, children in the active group (AG) showed significantly higher MEF50 compared to the control group (CG) (p=0.009).
  • The nutraceutical intervention appeared to prevent a decline in MEF50 in children with allergic rhinoconjunctivitis.

Conclusions:

  • A course of a multicomponent nutraceutical may help prevent the decline of MEF50 in children suffering from allergic rhinoconjunctivitis.
  • This intervention could be a strategy to manage early bronchial involvement in pediatric allergic rhinoconjunctivitis.

More Related Videos

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

10.7K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.1K

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.5K
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
3.6K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K